PhytoCeutica
Phytoceutica, Inc. develops FDA-approved cancer drugs from traditional Chinese medicine, focusing on quality control and reproducibility.
Founded
1999Phytoceutica, Inc. develops FDA-approved cancer drugs from traditional Chinese medicine, focusing on quality control and reproducibility.
Founded with a mission to transform traditional Chinese medicine into FDA-approved cancer treatments, PhytoCeutica, Inc. focuses on preclinical studies, clinical investigations, and botanical quality control. The company offers products like PHY906, a four-herb formula that mitigates chemotherapy's toxic effects while enhancing its antitumor efficacy, and PHY626, a herbal extract rich in amino acids. PhytoCeutica aims to bridge the gap between ancient remedies and modern oncology, targeting cancer patients seeking complementary and integrative treatment options.
Notable figures affiliated with PhytoCeutica include experts in oncology and pharmacology, though specific names are not provided. The company has achieved significant milestones in developing its flagship products, particularly PHY906, which has shown promise in clinical trials. PhytoCeutica's impact lies in its innovative approach to cancer treatment, potentially offering safer and more effective therapeutic options by integrating traditional medicine with contemporary scientific rigor.
Companies similar to PhytoCeutica include Phytomedics, Hylapharm, CBA Pharma and L.E.A.F. Pharmaceuticals.
PhytoCeutica was founded in 1999.
PhytoCeutica's headquarters is located in New Haven, CT, US.
PhytoCeutica's most recent funding round was for $2M (USD) in December 2010.
As of Dec 1, 2010, PhytoCeutica has disclosed funding of $2M (USD). Undisclosed round amounts are excluded.
PhytoCeutica has 5 employees as of Feb 5, 2024.
L.E.A.F. Pharmaceuticals
